BridgeBio Oncology Therapeutics, Inc. (BBOT) stock
Close on Nov 11, 2026Market cap $205.25MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $205.25M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.70
- Dividend yield
- –
- Free cash flow yield
- -73.59%
Fundamentals
- Net income
- -$171.53M
- EPS, diluted
- -$4.30
- Free cash flow
- -$151.03M
- Book value per share
- $3.66
- Diluted shares
- 80M
Trading
- Next earnings
- Mar 4, 2027 (estimated, after the close)
- Previous close
- $2.20
- Open
- $2.33
- Day's range
- $2.25 – $2.65
- Volume
- 1,423,904
- Average volume (20 days)
- 688,795
- Beta (5 years)
- 0.57
- 52-week range
- $1.98 – $14.87
- RSI (14 days)
- 40.1
- Volatility (1 year)
- 74.1%
- Relative volume
- 2.81×
- WACC
- 7.7%
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | BBOT | S&P 500 | Difference | BBOT per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -22.7% | -2.4% | −20.2 pts | ||
| 3 months | -72.2% | -1.2% | −71.0 pts | ||
| Year to date | -79.6% | +12.3% | −91.8 pts | ||
| 1 year | -79.9% | +12.4% | −92.4 pts |
Four years at a glance
Fiscal years 2022 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases BridgeBio Oncology Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- News
- Results
- Results
- Update
About BridgeBio Oncology Therapeutics
Pharmaceutical Preparations
BridgeBio Oncology Therapeutics, Inc. is a clinical-stage biotechnology company that discovers and develops targeted therapies for patients with cancers driven by RAS and PI3Kα oncogenes. The company focuses on addressing conditions such as lung, breast, pancreatic, and colon cancers. Its pipeline consists of orally bioavailable small-molecule inhibitors designed to target active and inactive conformations of oncogenic drivers. Its key development programs include BBO-8520, an inhibitor targeting KRAS G12C in non-small cell lung cancer; BBO-11818, a pan-KRAS inhibitor addressing various KRAS mutations; and BBO-10203. The company currently has no commercialized products, and its treatments are intended for oncology patients with specific genetic mutations.
Company profile, executives and historyBridgeBio Oncology Therapeutics stock: common questions
What is BridgeBio Oncology Therapeutics's stock price?
BBOT closed at $2.56 on Nov 11, 2026, up 16.36% on the day. Over the past 52 weeks it traded between $1.98 and $14.87.
What is BridgeBio Oncology Therapeutics's market cap?
BridgeBio Oncology Therapeutics was worth $205.25M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is BBOT's P/E ratio?
BridgeBio Oncology Therapeutics lost money over fiscal 2025 (diluted EPS -$4.30), so it has no meaningful P/E ratio.
Does BridgeBio Oncology Therapeutics pay a dividend?
No. BridgeBio Oncology Therapeutics has not paid a cash dividend over the last twelve months.
When does BridgeBio Oncology Therapeutics report earnings next?
BridgeBio Oncology Therapeutics is expected to report Q4 FY2026 results on Mar 4, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has BBOT stock performed over the past year?
Including dividends, BBOT returned -79.9% over the past year, against +12.4% for the S&P 500.
How many BBOT shares are sold short?
3M shares were sold short at the latest FINRA report, 8.18% of the float, or 5.1 days of average trading volume.
Who are BridgeBio Oncology Therapeutics's competitors?
Companies most similar to BridgeBio Oncology Therapeutics by business, industry and size include BOLD, ORIC, IDYA, PRLD, TNGX.
See a number that looks wrong?